Gene Synthesis Market Size, Share and Growth Outlook, 2026

Gene Synthesis Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Gene Synthesis Market size is forecast to increase from $6.71 Billion in 2026 to $21.85 Billion in 2034 at a CAGR of 15.9% between 2026 and 2034.

The Gene Synthesis market report provides detailed analysis and outlook of Gene Synthesis segments including By Synthesis Method (Chemical Oligonucleotide Synthesis, Enzymatic DNA Synthesis, Gene Assembly Technologies), By Service Type (Custom Gene Synthesis, Antibody DNA Synthesis, Viral Gene Synthesis, Large-scale), By Application (Gene & Cell Therapy Development, Vaccine Development, Disease Diagnosis, Agricultural Biotechnology, Metabolic Engineering), By End-User (Biopharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, Contract Development & Manufacturing Organizations) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Gene Synthesis Industry Overview

Advancing Synthetic Biology Through Automated DNA Production Technologies

The gene synthesis industry is experiencing significant technological advancement as synthetic biology, genetic engineering, pharmaceutical research, and biotechnology development increasingly rely on rapid and accurate DNA construction capabilities. Gene synthesis technologies enable researchers to design and manufacture custom DNA sequences for applications ranging from therapeutic development and vaccine research to industrial biotechnology and agricultural innovation. Growing demand for faster turnaround times, decentralized production models, and scalable synthetic biology workflows is driving investment in automated synthesis platforms and next-generation manufacturing technologies. The industry is steadily transitioning from centralized production systems toward flexible, laboratory-based synthesis environments that support on-demand genetic material generation.

Decentralized Enzymatic DNA Synthesis Expanding Global Accessibility

A major trend shaping the gene synthesis industry is the adoption of enzymatic DNA synthesis technologies that enable localized production of oligonucleotides and genetic constructs. DNA Script expanded the international reach of its SYNTAX Platform through major distribution agreements with Gencell in Latin America, Bio-Medical Science Co. in South Korea, and Biostream in Japan. The SYNTAX Platform utilizes enzymatic DNA synthesis technology within a compact benchtop system that allows laboratories to manufacture oligonucleotides directly on-site. This decentralized production model reduces reliance on centralized international supply chains and provides researchers with greater control over synthesis timelines. The growing adoption of automated enzymatic synthesis platforms reflects the industry's movement toward more agile, responsive, and regionally accessible gene synthesis capabilities.

High-Throughput Bio-Foundries Accelerating Custom Gene Production

Automation and advanced manufacturing workflows are transforming the speed and scalability of gene synthesis operations. Eurofins Genomics and other leading synthesis providers have introduced optimized high-throughput configurations that significantly improve custom gene production efficiency. These systems transition traditional gene synthesis workflows into highly automated bio-foundry environments capable of handling large volumes of synthesis requests with enhanced precision and consistency. By combining enzymatic synthesis approaches with microchip-based phosphoramidite array technologies, manufacturers have dramatically reduced the time required to generate fully verified clonal genes. Turnaround periods that previously required extended production cycles can now be completed within hours, enabling faster support for biopharmaceutical contract development and manufacturing organizations, research institutions, and synthetic biology programs. These innovations are strengthening the industry's ability to meet growing demand for rapid, high-fidelity gene synthesis across diverse life sciences applications.

Gene Synthesis Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Gene Synthesis market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- GenScript Biotech Corporation, Twist Bioscience Corporation, Thermo Fisher Scientific Inc. (GeneArt), IDT (Integrated DNA Technologies) – Danaher Corporation, Merck KGaA, Eurofins Genomics, Azenta Life Sciences (GeneWiz), Telesis Bio (Codex DNA), DNA Script, BBI Life Sciences Corporation. The Gene Synthesis market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Gene Synthesis industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Gene Synthesis Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Gene Synthesis companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Gene Synthesis markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Gene Synthesis Market Competitive Benchmarking and Company Analysis

Leading companies in Gene Synthesis industry include- GenScript Biotech Corporation, Twist Bioscience Corporation, Thermo Fisher Scientific Inc. (GeneArt), IDT (Integrated DNA Technologies) – Danaher Corporation, Merck KGaA, Eurofins Genomics, Azenta Life Sciences (GeneWiz), Telesis Bio (Codex DNA), DNA Script, BBI Life Sciences Corporation. The Gene Synthesis market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Gene Synthesis Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Gene Synthesis market remains one of the strongest-performing segments in the country.
The US Gene Synthesis Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Gene Synthesis market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Gene Synthesis industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Gene Synthesis markets

Canada's strong Gene Synthesis sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Gene Synthesis market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Gene Synthesis Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Gene Synthesis market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Gene Synthesis population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Gene Synthesis industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Gene Synthesis market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Gene Synthesis sales through 2034

France Gene Synthesis companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Gene Synthesis Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Gene Synthesis distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Gene Synthesis Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Gene Synthesis market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Gene Synthesis industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Gene Synthesis industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Gene Synthesis Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Gene Synthesis market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Gene Synthesis market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Gene Synthesis Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Gene Synthesis Market Segmentation

By Synthesis Method
Chemical Oligonucleotide Synthesis
Enzymatic DNA Synthesis
Gene Assembly Technologies
By Service Type
Custom Gene Synthesis
Antibody DNA Synthesis
Viral Gene Synthesis
Large-scale
By Application
Gene & Cell Therapy Development
Vaccine Development
Disease Diagnosis
Agricultural Biotechnology
Metabolic Engineering
By End-User
Biopharmaceutical & Biotechnology Companies
Academic & Government Research Institutes
Contract Development & Manufacturing Organizations

Top Companies in Gene Synthesis Industry

GenScript Biotech Corporation
Twist Bioscience Corporation
Thermo Fisher Scientific Inc. (GeneArt)
IDT (Integrated DNA Technologies) – Danaher Corporation
Merck KGaA
Eurofins Genomics
Azenta Life Sciences (GeneWiz)
Telesis Bio (Codex DNA)
DNA Script
BBI Life Sciences Corporation

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa